In FY21, revenue at Molbio Diagnostics jumped 25 times in a single year, from ₹51.53 crore to ₹1,272 crore, as its Truenat machine became a frontline tool in India’s pandemic testing effort (Entrackr, July 2022). Two years later the same company posted a loss, because the market it had leaned on for that growth — COVID-19 testing — had largely disappeared (Entrackr, June 2024).
This is the story of a two-decade molecular-diagnostics project out of Goa that turned a tuberculosis testing mandate into a recurring, government-anchored revenue line, survived that boom-and-bust cycle, and listed on the Indian stock exchanges in August 2026 at a market value of about ₹15,085 crore (~$1.57 billion at $1 ≈ ₹96.0 as of 18 September 2026, Trading Economics) (Screener.in, September 2026).
Quick facts
| Company | Molbio Diagnostics Limited |
| Founded | 2000, Goa (Sriram Natarajan); commercial joint venture with Bigtec Labs formed 2011, merged into Molbio in 2015 (Molbio Diagnostics Heritage page; Wikipedia, accessed September 2026) |
| Founder(s) | Sriram Natarajan (CEO) and Dr Chandrasekhar Bhaskaran Nair (CTO, Bigtec Labs) |
| Businesses | Truenat point-of-care PCR platform for TB, COVID-19, HIV, hepatitis and other infections; digital X-ray (subsidiary Prognosys Medical Systems) and digital pathology (OptraScan) |
| Latest FY revenue | ₹1,445.69 crore, FY26 (year ended March 2026), as per RHP (Bajaj Broking, August 2026) |
| Latest FY profit/loss | ₹164.14 crore profit, FY26 (Bajaj Broking, August 2026) |
| Listed | Yes — BSE (544866) and NSE (MOLBIO), listed 17 August 2026 (Chittorgarh, August 2026) |
| Market value / last valuation | About ₹15,085 crore market capitalisation (Screener.in, September 2026); IPO priced the company at roughly ₹8,900 crore at the ₹807 issue price |
| Key shareholders / CEO | Sriram Natarajan (CEO); pre-IPO holders included Exxora Trading LLP (~41.2%), India Business Excellence Fund (~12.7%) and Temasek Holdings (~8.9%) (Screener.in, September 2026) |
What they do
Molbio Diagnostics builds and sells Truenat, a battery-powered, portable real-time PCR system that runs molecular diagnostic tests outside a conventional lab — in a district hospital, a mobile testing van or a primary health centre with unreliable power. The company’s largest and best-known use case is tuberculosis: Truenat is one of only two point-of-care molecular tests globally endorsed by the World Health Organization for initial TB detection, and its chip-based test is the only such rapid molecular TB test built by an Indian company (Bajaj Broking, citing the company’s RHP, August 2026). Beyond TB, the platform runs assays for COVID-19, HIV, hepatitis, dengue, chikungunya, HPV and other infectious diseases, and by FY26 the company reported the platform in use across more than 90 countries (Groww, August 2025; Bajaj Broking, August 2026). Its customers are overwhelmingly institutional — government TB and public-health programmes, international aid agencies, and hospital and laboratory networks — rather than individual patients paying out of pocket.
The origin
Sriram Natarajan was not a first-time founder when he started what became Molbio in Goa in 2000. He had built Tulip Diagnostics, an in-vitro diagnostics reagent maker, into one of India’s largest IVD exporters before exiting that business in January 2017, according to his own professional biography (Somerset Indus Capital Partners; StartupTalky, accessed September 2026). Around the same time, Dr Chandrasekhar Nair was running Bigtec Labs, a Bengaluru lab-on-a-chip research outfit, on a narrower bet: that a PCR test — the gold standard for detecting infections at the genetic level — could be shrunk onto a chip small and cheap enough to run in a village clinic rather than a metro hospital lab. The founding insight was less about a single invention and more about a structural gap: India’s disease burden was concentrated in places without lab infrastructure, and a decentralised, chip-based molecular test could reach patients that centralised labs never would. In 2004, Bigtec narrowed its research entirely onto chip-based PCR systems, and Natarajan’s commercial network gave that hardware a path to the field once it worked (Molbio Diagnostics Heritage page, accessed September 2026).
The struggle years
The unsoftened version of Molbio’s history is that it spent roughly thirteen years as a research project before it looked like a business. Bigtec Labs reached only a proof-of-concept for point-of-care real-time PCR in 2008, eight years after Natarajan and Nair began working in the same direction (Molbio Diagnostics Heritage page, accessed September 2026). It took until 2011 for the two entities to formalise a joint venture to commercialise what became Truenat, and until 2013 for the first real-world deployment, in Bihar, reaching patients outside the traditional lab system (Molbio Diagnostics Heritage page, accessed September 2026). The two organisations did not even merge into one company until 2015, with Bigtec folded in as Molbio’s dedicated R&D arm.
The second, more public setback came after the company had already scaled. Revenue had gone from ₹51.53 crore in FY20 to ₹1,272 crore in FY21 on COVID-19 testing demand, with profit of ₹472.7 crore that year (Entrackr, July 2022). By FY22, as pandemic testing volumes eased, revenue had already nearly halved to ₹776 crore, though profit still held at ₹215 crore. FY23 was the real reversal: revenue fell a further 57% to ₹332 crore, and the company slipped to a loss of about ₹3.4 crore, as fixed costs built for pandemic-era volumes could not be shed as fast as demand fell (Entrackr, June 2024). A business that had looked, for one year, like a generational pandemic winner had to prove it could survive without a pandemic.
The turning point
The single event that reshaped Molbio’s trajectory was India’s regulatory approval of Truenat for COVID-19 RT-PCR testing in 2020, layered onto the WHO’s endorsement of the same platform for tuberculosis detection that same year. Before that approval, Molbio was a modest, TB-focused diagnostics supplier: FY20 revenue was ₹51.53 crore, on a loss of ₹16.27 crore (Entrackr, July 2022). After it, FY21 revenue reached ₹1,272 crore — a 25-fold jump in one fiscal year — with profit of ₹472.7 crore, more than 4,000 Truenat machines deployed, and Truenat-branded product collections alone growing 40 times to ₹797.6 crore (Entrackr, July 2022). The pandemic did not create Molbio’s technology or its TB relationships with government health programmes; both existed already, built over the previous decade. What COVID-19 did was force adoption at a speed and scale the company could not have achieved through its original TB channel alone, and it left behind a manufacturing base, a distribution network and government relationships that TB testing alone continued to use well after COVID-19 volumes faded.
The money behind it
- Motilal Oswal (Motilal Oswal Private Equity / Alternates) — an early institutional backer that stayed in through the company’s pandemic swing and its 2022 unicorn round (Molbio Diagnostics newsroom, September 2022).
- Temasek Holdings — invested $85 million in September 2022, the round that pushed Molbio’s valuation past $1 billion and made it India’s 108th unicorn (Molbio Diagnostics newsroom, September 2022; The Better India, September 2022).
- India Business Excellence Fund — held roughly 12.7% of pre-IPO equity, among the largest institutional stakes alongside Temasek’s roughly 8.9% (Screener.in, September 2026).
- Total funding raised before the IPO — reported figures differ: Screener.in-derived data puts total funding raised at approximately ₹970 crore, while Crunchbase lists total funding of $124 million (roughly ₹1,190 crore at the FX rate above) across four rounds and 38 investors; both are given here since they do not fully reconcile (Screener.in, September 2026; Crunchbase, accessed September 2026).
- IPO, August 2026 — a ₹939.70 crore issue: ₹200.12 crore fresh issue plus an offer for sale of ₹739.57 crore by existing shareholders, priced at ₹807 per share (top of a ₹768–807 band), subscribed 49.35 times, and listed on the BSE and NSE on 17 August 2026 at roughly a 28.5% premium to the issue price (Chittorgarh, August 2026).
- What each investor changed — Motilal Oswal’s early backing funded the manufacturing scale-up that let Molbio meet COVID-era demand; Temasek’s 2022 cheque and unicorn tag opened the credibility needed for an IPO track within four years; the IPO itself converted founder and early-investor paper wealth into a listed, liquid stock and funded a new R&D centre of excellence and manufacturing equipment (Bajaj Broking, August 2026).
How it makes money
Molbio’s business model is closer to a razor-and-blade hardware company than a diagnostics-services chain. It sells the Truenat device (a “micro PCR workstation”) largely once, then earns recurring revenue every time that device runs a test, because each test consumes a proprietary single-use chip and reagent kit. The part people commonly get wrong is assuming Molbio operates like a pathology lab chain (testing patients directly and billing them); in practice its direct customers are governments, aid agencies, hospitals and laboratories who then run the tests, not patients.
- Instrument sales — Truenat micro PCR workstations; ₹253 crore of FY21 revenue, roughly a fifth of that year’s total, as the pandemic drove device placements (Entrackr, July 2022).
- Consumables (reagent kits and cartridges) — the recurring, per-test revenue line; ₹216.6 crore in FY21, up 43 times year-on-year as installed devices ran more tests (Entrackr, July 2022).
- Truenat product collections (combined device plus kit sales reported together) — ₹797.6 crore in FY21, the bulk of that year’s revenue (Entrackr, July 2022).
- Other services — a small residual line, ₹4.8 crore in FY21 (Entrackr, July 2022).
- Cost structure — raw materials and medical components are consistently the largest cost line, running 44–59% of total expenses across the years reported (₹370 crore of FY21 costs; ₹143 crore, 44% of FY23 costs; ₹413 crore, over half of FY25 costs) (Entrackr, July 2022; Entrackr, June 2024; Entrackr, September 2025).
- Margin trend — EBITDA margin swung from 48% in FY22 to 14.5% in FY23 as pandemic volumes collapsed, then recovered to 26.17% in FY25 and an estimated 22.7% in FY26 on the RHP’s EBITDA and revenue figures (Entrackr, June 2024; Entrackr, September 2025; Bajaj Broking, August 2026).
The numbers
Figures below are drawn from the company’s Red Herring Prospectus as reported by Bajaj Broking (August 2026); all figures in ₹ crore.
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue from operations | 836.56 | 1,020.42 | 1,445.69 |
| EBITDA | 185.09 | 256.64 | 328.24 |
| Net profit (PAT) | 83.54 | 138.58 | 164.14 |
| Net worth | 807.94 | 952.95 | 1,144.68 |
- Revenue grew 22.0% in FY25 over FY24, then 41.7% in FY26 over FY25, the year of the IPO (calculated from the table above; Bajaj Broking, August 2026).
- Net profit nearly doubled from FY24 to FY25 (₹83.54 crore to ₹138.58 crore) before rising a further 18.4% in FY26 (Bajaj Broking, August 2026).
- For longer-run context, FY25 test kit sales alone (₹730.96 crore) already exceeded the company’s entire FY24 revenue base of test kit sales (₹552.55 crore), showing kits, not devices, driving the recovery (Entrackr, September 2025).
- Truenat devices sold in FY25: 2,180 units; test kits sold in FY25: 12.24 million units (Entrackr, September 2025).
Where the money comes from
- Customer type, FY26 — government bodies and international aid agencies contributed 84.56% of revenue from finished goods (Bajaj Broking, citing the RHP, August 2026).
- Product concentration, FY26 — TB test kits alone made up 70.20% of finished-goods revenue (Bajaj Broking, citing the RHP, August 2026).
- Customer concentration, FY26 — the top 10 customers accounted for 83.26% of finished-goods revenue (Bajaj Broking, citing the RHP, August 2026).
- Geography, FY25 — revenue from customers outside India was about ₹197 crore of ₹1,027.94 crore total revenue, roughly 19%, with the remaining ~81% from domestic sales, despite the platform being sold in more than 90 countries (Groww, August 2025; Bajaj Broking, August 2026).
- The surprise — a company that markets itself on global reach (90-plus countries) still earns about four out of every five rupees at home, and roughly seven in ten of the finished-goods rupees from one disease category, tuberculosis, even after 25 years in the field and a stock market listing.
The risks
- Government and aid-agency dependence — 84.56% of FY26 finished-goods revenue came from government and international aid agency buyers, so a change in a national TB programme’s budget or procurement process can move the topline directly (Bajaj Broking, citing the RHP, August 2026).
- Single-disease concentration — TB test kits were 70.20% of FY26 finished-goods revenue; a rival technology, a pricing change in a public tender, or a shift in WHO-recommended testing protocol would hit a large share of revenue at once (Bajaj Broking, citing the RHP, August 2026).
- Customer concentration — the top 10 customers were 83.26% of FY26 finished-goods revenue, and the top 10 suppliers were 58.52% of raw-material and component purchases, creating risk on both the demand and supply side (Bajaj Broking, citing the RHP, August 2026).
- Demand cyclicality already demonstrated — the company’s own FY21–FY23 numbers show a 74% revenue decline from the FY21 pandemic peak to the FY23 trough, then recovery; a similar swing tied to any future outbreak cycle, up or down, is a disclosed and demonstrated pattern rather than a hypothetical one (Entrackr, June 2024).
- R&D execution risk — the RHP disclosed that only one of the new assays targeted for commercialisation in FY26 was actually commercialised that year, alongside leasehold (not owned) manufacturing and R&D sites (Bajaj Broking, citing the RHP, August 2026).
The takeaway
Molbio’s arc argues that a product built to serve a public-health mandate can become a durable, profitable business well before — and well after — any private market for it exists. TB testing gave Molbio guaranteed institutional demand for years when no retail market for a portable PCR machine existed at all, and that same government relationship is what let the company pivot into COVID-19 testing almost overnight in 2020. But the same concentration that built the company is now its most disclosed risk: a single disease category and a single class of institutional buyer still decide most of the topline, a full IPO cycle later. The lesson is not that mission-driven, government-anchored businesses are safer or riskier than consumer ones by default; it is that the concentration a founder accepts to get to scale rarely goes away once the company is large — it just gets written into the risk-factors section of a prospectus instead.
Frequently asked questions
What does Molbio Diagnostics make?
Molbio makes Truenat, a portable, battery-powered real-time PCR testing platform used to diagnose tuberculosis, COVID-19, HIV, hepatitis and other infectious diseases at the point of care, without a conventional lab (Bajaj Broking, August 2026).
Is Molbio Diagnostics a listed company?
Yes. Molbio Diagnostics Limited listed on the BSE (544866) and NSE (MOLBIO) on 17 August 2026 after an IPO priced at ₹807 per share (Chittorgarh, August 2026).
Who founded Molbio Diagnostics?
Sriram Natarajan founded Molbio in Goa in 2000; Dr Chandrasekhar Bhaskaran Nair’s Bengaluru lab, Bigtec Labs, developed the underlying chip-based PCR technology and formally joined with Molbio via a 2011 joint venture, merging fully in 2015 (Molbio Diagnostics Heritage page, accessed September 2026).
How much revenue does Molbio Diagnostics make?
Revenue from operations was ₹1,445.69 crore in FY26 (year ended March 2026), up from ₹1,020.42 crore in FY25 and ₹836.56 crore in FY24 (Bajaj Broking, August 2026).
What is Molbio’s biggest business risk?
Concentration: government and aid-agency buyers were 84.56% of FY26 finished-goods revenue, and TB test kits alone were 70.20% of that revenue, as disclosed in the company’s IPO prospectus (Bajaj Broking, citing the RHP, August 2026).
Sources
Figures are as of September 2026. Currency converted at $1 ≈ ₹96.0 as of 18 September 2026 (Trading Economics).
- Entrackr, “From Rs 51 Cr in FY20 to Rs 1,272 Cr revenue in FY21: The story of Molbio Diagnostics”, July 2022
- Entrackr, “After Rs 215 Cr profit in FY22, Molbio reports Rs 3 Cr loss in FY23”, June 2024
- Entrackr, “Molbio Diagnostics posts Rs 1,020 Cr revenue and Rs 138 Cr PAT in FY25”, September 2025
- Bajaj Broking, “Molbio Diagnostics Limited IPO Details: RHP, Financials & Key Risks”, August 2026
- Chittorgarh.com, “Molbio Diagnostics IPO Date, Price, GMP, Review, Details”, August 2026
- Groww, “Upcoming IPO: Molbio Diagnostics files DRHP with SEBI for IPO”, August 2025
- Molbio Diagnostics newsroom, “Molbio Diagnostics turns unicorn after raising $85M from Temasek, Motilal Oswal Alternates”, September 2022
- The Better India, “This Diagnosis Startup from Goa Revolutionised COVID-19 Tests; Now Raised $85 Million”, September 2022
- Molbio Diagnostics, “Heritage” (company history page, molbiodiagnostics.com), accessed September 2026
- Wikipedia, “Molbio Diagnostics”, accessed September 2026
- Screener.in, Molbio Diagnostics Ltd company page, accessed September 2026
- Crunchbase, Molbio Diagnostics organization profile, accessed September 2026
- Somerset Indus Capital Partners / StartupTalky, biography of Sriram Natarajan, accessed September 2026
Found an error? Write to us and we’ll correct it in the open, dated, on the piece.